Last reviewed 2026-05-14 · How we verify

Dorzolamide-timolol-brimonidine and latanoprost

Dorzolamide-timolol-brimonidine and latanoprost is a Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, alpha-2 agonist, and prostaglandin analog Small molecule drug developed by Laboratorios Sophia S.A de C.V.. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension. Also known as: PRO-122, Krytantek Ofteno PF®, Gaap Ofteno PF®.

This fixed-dose combination reduces intraocular pressure through four complementary mechanisms: carbonic anhydrase inhibition, beta-adrenergic blockade, alpha-2 adrenergic agonism, and prostaglandin F analog activity.

This fixed-dose combination reduces intraocular pressure through four complementary mechanisms: carbonic anhydrase inhibition, beta-adrenergic blockade, alpha-2 adrenergic agonism, and prostaglandin F analog activity. Used for Open-angle glaucoma, Ocular hypertension.

At a glance

Mechanism of action

Dorzolamide inhibits carbonic anhydrase to decrease aqueous humor production. Timolol is a non-selective beta-blocker that reduces aqueous humor secretion. Brimonidine is an alpha-2 agonist that decreases aqueous humor production and increases uveoscleral outflow. Latanoprost is a prostaglandin F analog that increases uveoscleral outflow. Together, these four agents provide additive intraocular pressure reduction.

Approved indications

• Open-angle glaucoma
• Ocular hypertension

Common side effects

• Ocular irritation/hyperemia
• Blurred vision
• Allergic conjunctivitis
• Systemic beta-blocker effects (bradycardia, fatigue)
• Dry mouth

Key clinical trials

• Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
• How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure? (PHASE4)
• Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (PHASE4)
• Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
• Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves (PHASE4)
• Transconjunctival Needling Revision Versus Medical Treatment (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Dorzolamide-timolol-brimonidine and latanoprost CI brief — competitive landscape report
• Dorzolamide-timolol-brimonidine and latanoprost updates RSS · CI watch RSS
• Laboratorios Sophia S.A de C.V. portfolio CI

Frequently asked questions about Dorzolamide-timolol-brimonidine and latanoprost

Related

• Drug class: All Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, alpha-2 agonist, and prostaglandin analog drugs
• Target: All drugs targeting Carbonic anhydrase II, beta-2 adrenergic receptor, alpha-2A adrenergic receptor, prostaglandin F receptor
• Manufacturer: Laboratorios Sophia S.A de C.V. — full pipeline
• Therapeutic area: All drugs in Ophthalmology
• Indication: Drugs for Open-angle glaucoma
• Indication: Drugs for Ocular hypertension
• Also known as: PRO-122, Krytantek Ofteno PF®, Gaap Ofteno PF®
• Compare: Dorzolamide-timolol-brimonidine and latanoprost vs similar drugs
• Pricing: Dorzolamide-timolol-brimonidine and latanoprost cost, discount & access